Enanta Pharmaceuticals, Inc.
ENTA
$8.53
-$0.12-1.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.43% | 27.32% | 33.28% | -2.55% | 42.00% |
| Total Depreciation and Amortization | 103.70% | 93.72% | 38.47% | -28.40% | -8.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.04% | 10.62% | -51.01% | 2,460.22% | -38.89% |
| Change in Net Operating Assets | 1,098.59% | 163.04% | 108.18% | 47.62% | 318.93% |
| Cash from Operations | 218.48% | 52.84% | 32.76% | 51.86% | 54.01% |
| Capital Expenditure | 97.63% | -52.16% | -1,011.18% | -554.31% | -204.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13,464.47% | -103.04% | 729.75% | 112.24% | 100.14% |
| Cash from Investing | -317.38% | -107.45% | 625.30% | 61.14% | 95.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -- | -- | -86.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.76% | -6.53% | 30.88% | -31,565.22% | -103.34% |
| Cash from Financing | 3.35% | -7.37% | 32.16% | -31,269.57% | -103.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.53% | -204.81% | 203.65% | 114.89% | -226.22% |